JP2014193816A - 脂肪組織の慢性炎症抑制剤 - Google Patents
脂肪組織の慢性炎症抑制剤 Download PDFInfo
- Publication number
- JP2014193816A JP2014193816A JP2013070017A JP2013070017A JP2014193816A JP 2014193816 A JP2014193816 A JP 2014193816A JP 2013070017 A JP2013070017 A JP 2013070017A JP 2013070017 A JP2013070017 A JP 2013070017A JP 2014193816 A JP2014193816 A JP 2014193816A
- Authority
- JP
- Japan
- Prior art keywords
- adipose tissue
- ginger
- chronic inflammation
- group
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 41
- 208000037976 chronic inflammation Diseases 0.000 title claims abstract description 32
- 230000006020 chronic inflammation Effects 0.000 title claims abstract description 32
- 239000003112 inhibitor Substances 0.000 title claims abstract description 15
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 48
- 235000008397 ginger Nutrition 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 4
- 239000001841 zingiber officinale Substances 0.000 claims abstract description 4
- 241000234314 Zingiber Species 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 11
- 229930091371 Fructose Natural products 0.000 description 11
- 239000005715 Fructose Substances 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 7
- 239000010931 gold Substances 0.000 description 7
- 229910052737 gold Inorganic materials 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- FXLJDRXREUZRIC-BAOOBMCLSA-N (3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO FXLJDRXREUZRIC-BAOOBMCLSA-N 0.000 description 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100025136 Macrosialin Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000273590 Asarum canadense Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101100532034 Drosophila melanogaster RTase gene Proteins 0.000 description 1
- 206010016251 Fat tissue increased Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108091077196 LAMP family Proteins 0.000 description 1
- 102000041237 LAMP family Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- -1 auxiliaries Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000018406 regulation of metabolic process Effects 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】本発明に係る脂肪組織の慢性炎症抑制剤は、ショウガ(Zingiber Officinale)またはその抽出物を有効成分として含有することを特徴とする。
【選択図】なし
Description
粗切した乾燥金時ショウガ(平成23年,ベトナム ダナン近郊栽培品)5kgに95v/v%エタノール水溶液5Lを加え時々振り混ぜ、室温で24時間冷浸後、3時間加熱還流した。室温まで放冷した後に濾過し、得られた濾液を45℃で減圧濃縮して溶媒を完全に留去し、金時ショウガアルコールエキスを得た。ショウガ原料からの収率は9.6%であった。また、得られたエキス中のジンゲロール含有量を日本薬局方ショウキョウ末の定量法に準じて測定したところ、4.40質量%であった。
(1) 白色脂肪組織試料の採取
体重210〜230gの雄性SD系ラットを、21±1℃、湿度55±5%、12時間毎の明暗室で、固形飼料と水を自由に与えつつ1週間予備飼育した。次いで、18匹のラットを任意に6匹ずつの3グループに分けた。第1群には、予備飼育と同様の条件で飼育を継続した。第2群には、水の代わりに10%果糖水を与えた。第3群には、10%果糖水に加え、上記実施例1の金時ショウガアルコールエキスを50mg/kgの割合で5週間にわたり毎日経口投与した。
上記で得られたeWATの一部を10%ホルマリン液で固定し、パラフィンに包埋し、10μm片にカットした。ヘマトキシリン・エオジン染色し、倒立型電動リサーチ顕微鏡(オリンパス社製,IX81)を用いて脂肪組織の形状を観察した。結果を図1に示す。図1(1)〜(3)は、それぞれ、第1群(水のみ摂取の対照群)、第2群(10%果糖摂取群)、第3群(10%果糖摂取+金時ショウガアルコールエキス投与群)の脂肪組織の拡大写真である。
RNA抽出用試薬(Invitrogen社製,TRIzol(登録商標))を使い、eWATから総RNAを抽出した。得られた総RNAから、M−MLV RTase cDNAシステムキットを用いてcDNAを合成した。得られたcDNA、CFX96リアルタイムPCR検出システム(Bio−rad Laboratories社製,Hercules,CA,USA)およびリアルタイムPCR専用試薬(タカラバイオ社製,SYBR(登録商標)PremixEX TaqTMII)を用い、リアルタイムPCRを行った。使用したプライマーの配列を表1に示す。なお、各サンプルの遺伝子発現は2回行い、対照のβ−actinに対して標準化した。また、リアルタイムPCRの結果を図2に示す。図2(1)はCD68、(2)はF4/80、(3)はTNF−α、(4)はIL−6、(5)はMCP−1、(6)はCCR−2を示す。
Claims (3)
- ショウガ(Zingiber Officinale)またはその抽出物を有効成分として含有することを特徴とする脂肪組織の慢性炎症抑制剤。
- ショウガのアルコール抽出物またはアルコール水溶液抽出物を有効成分として含む請求項1に記載の脂肪組織の慢性炎症抑制剤。
- アルコールがエタノールである請求項2に記載の脂肪組織の慢性炎症抑制剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013070017A JP2014193816A (ja) | 2013-03-28 | 2013-03-28 | 脂肪組織の慢性炎症抑制剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013070017A JP2014193816A (ja) | 2013-03-28 | 2013-03-28 | 脂肪組織の慢性炎症抑制剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2014193816A true JP2014193816A (ja) | 2014-10-09 |
Family
ID=51839371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013070017A Pending JP2014193816A (ja) | 2013-03-28 | 2013-03-28 | 脂肪組織の慢性炎症抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2014193816A (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005075749A (ja) * | 2003-08-29 | 2005-03-24 | National Agriculture & Bio-Oriented Research Organization | 細胞分化促進剤 |
JP2005112829A (ja) * | 2003-10-02 | 2005-04-28 | Katsutoshi Terasawa | アルドース還元酵素阻害薬 |
JP2006045210A (ja) * | 2004-07-08 | 2006-02-16 | National Institute Of Advanced Industrial & Technology | アディポネクチン産生増強剤 |
JP2008189571A (ja) * | 2007-02-02 | 2008-08-21 | Oriza Yuka Kk | 糖尿病及び/又は肥満の治療・予防剤 |
JP2009019061A (ja) * | 2004-03-18 | 2009-01-29 | Sakamoto Yakusoen:Kk | Ppar活性化作用を有する健康食品およびppar活性化剤 |
-
2013
- 2013-03-28 JP JP2013070017A patent/JP2014193816A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005075749A (ja) * | 2003-08-29 | 2005-03-24 | National Agriculture & Bio-Oriented Research Organization | 細胞分化促進剤 |
JP2005112829A (ja) * | 2003-10-02 | 2005-04-28 | Katsutoshi Terasawa | アルドース還元酵素阻害薬 |
JP2009019061A (ja) * | 2004-03-18 | 2009-01-29 | Sakamoto Yakusoen:Kk | Ppar活性化作用を有する健康食品およびppar活性化剤 |
JP2006045210A (ja) * | 2004-07-08 | 2006-02-16 | National Institute Of Advanced Industrial & Technology | アディポネクチン産生増強剤 |
JP2008189571A (ja) * | 2007-02-02 | 2008-08-21 | Oriza Yuka Kk | 糖尿病及び/又は肥満の治療・予防剤 |
Non-Patent Citations (2)
Title |
---|
株式会社メルシャンクリンテック: "メタボリックシンドロームと疾患モデル", フナコシレビューNO.1[ONLINE], JPN6016050437, 31 March 2008 (2008-03-31), ISSN: 0003472743 * |
白川 純,寺内 康夫: "炎症性疾患としての肥満と栄養", 栄養-評価と治療, vol. 第28巻,第3号, JPN6016050436, August 2011 (2011-08-01), pages 218 - 221, ISSN: 0003472742 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6209579B2 (ja) | 補助化療薬品とされる医薬組成物その用途 | |
EP2992933B1 (en) | Ginsenoside f2 for prophylaxis and treatment of liver disease | |
Chiang et al. | Active food ingredients production from cold pressed processing residues of Camellia oleifera and Camellia sinensis seeds for regulation of blood pressure and vascular function | |
JP6189595B2 (ja) | 低アディポネクチン血症治療剤 | |
KR20210133909A (ko) | 함초 추출물을 포함하는 골 질환 또는 갱년기 질환의 예방 또는 치료용 조성물 | |
KR101683344B1 (ko) | 카르노식산을 유효성분으로 포함하는 갱년기 증상의 예방 또는 개선용 조성물 | |
JP5661309B2 (ja) | 抗肥満剤 | |
CN110693873B (zh) | 冬凌草活性成分组合物的制备及应用 | |
JP2014193816A (ja) | 脂肪組織の慢性炎症抑制剤 | |
JP6144564B2 (ja) | 炎症予防剤 | |
KR20160011570A (ko) | 금은화 추출물을 포함하는 항당뇨 및 항비만 효과 증진용 조성물 | |
JP6513404B2 (ja) | 脂肪燃焼促進剤及び低体温改善剤 | |
JP5548379B2 (ja) | 花粉荷を含有する抗ヒスタミン剤 | |
JP2008081425A (ja) | 内臓脂肪蓄積抑制剤 | |
JP6236489B2 (ja) | 逆流性食道炎治療薬 | |
KR102675186B1 (ko) | 벌개미취 물 추출물을 유효성분으로 포함하는 항비만용 조성물 | |
KR100573592B1 (ko) | 비만치료·억제용 백모근 추출물 | |
JP2011032256A (ja) | 薬用ニンジンを始めとしたサポニン含有生薬服用時に生じるメンゲン反応の防止及び生薬の吸収性を増大させる製法(生薬の有効成分を鶏卵タンパクに吸収させる方法)による医薬組成物及び健康食品 | |
JP2019052122A (ja) | アディポネクチン分泌促進剤、脂肪前駆細胞分化促進剤並びにそれらを含む医薬組成物、食品及び飼料 | |
WO2015041235A1 (ja) | 生活習慣病治療のための食品素材の使用 | |
KR101895850B1 (ko) | 벌씀바귀 추출물을 유효성분으로 함유하는 전립선 질환의 예방, 개선 또는 치료용 조성물 | |
JP6871737B2 (ja) | ウロプラキン発現促進剤 | |
KR20220084817A (ko) | 벌개미취 물 추출물을 유효성분으로 포함하는 항비만용 조성물 | |
TWI615147B (zh) | 黑蒜頭改善雄性動物精液品質之用途及性功能障礙的保健食品 | |
KR20160011571A (ko) | 황금 추출물을 포함하는 항당뇨 및 항비만 효과 증진용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170110 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170711 |